Domin® Tablet: Each film-coated tablet contains Domperidone maleate BP 12.726 mg equivalent to Domperidone 10 mg.
Domin® Suspension: Each 5 ml contains Domperidone BP 5 mg.
Domin® Pediatric Drops: Each ml contains Domperidone BP 5 mg.
Domin® 15 mg Suppository: Each Suppository contains Domperidone BP 15 mg.
Domin® 30 mg Suppository: Each Suppository contains Domperidone BP 30 mg.
Domperidone (Domin ) is a dopamine antagonist. Because it does not readily enter the central nervous system, its effects are confined to the periphery and acts principally at the receptor in the chemoreceptor trigger zone.
Mode of action:
Domperidone (Domin ) specifically antagonize the peripheral D2 dopamine receptor.
Pharmacokinetics:
Domperidone is rapidly and almost completely (93%) absorbed after oral administration. Peak plasma concentrations occur within 30 minutes after oral administration. The peak plasma concentration after 20 mg oral dose is in the range of 15 to 19 ng/ml. The mean elimination half-life ranges from 12 to 16 hrs for an oral dose. Domperidone is strongly bound to proteins (91-93%). Domperidone extensive biotransformation with <10% excreted unchanged in urine.
Dosage & administration: Adults: 10 to 20 mg every 4-8 hours daily. Children: 0.2- 0.4 mg/kg body weight every 4-8 hours daily. Domperidone should be taken 15-30 minutes before a meal. For acute nausea and vomiting, maximum period of treatment is 12 weeks.
Side effects: Domperidone may produce hyperprolactinemia. This may result in galactorrhoea, breast enlargement and soreness and reduced libido. Dry mouth, thirst headache, nervousness, drowsiness, diarrhoea, skin rash and itching may occur during treatment with Domperidone. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies.
Use in pregnancy & lactation: Pregnant women: The safety of Domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated teratogenic effects on the foetus.
Precautions: Domperidone should be used with absolute caution in case of children because there may be an increased risk of extrapyramidal reactions in young children because of an incompletely developed blood brain barrier.
Drug interactions: Domperidone may reduce the hypoprolactinemic effect of bromocriptine. The action of domperidone of GI function may be antagonized by antimuscarinics and opioid analgesics.
Storage: Store in a cool and dry place, protected from light.
Adults: 10 to 20 mg every 4-8 hours daily. Children: 0.2- 0.4 mg/kg body weight every 4-8 hours daily. Domperidone should be taken 15-30 minutes before a meal. For acute nausea and vomiting, maximum period of treatment is 12 weeks. By rectum in suppositories: Adult and child body weight over 35 kg: 60 mg twice daily; Child: 15-34 kg (nausea and vomiting only): 30 mg twice daily.
Domperidone may reduce the hypoprolactinemic effect of bromocriptine. The action of domperidone of GI function may be antagonized by antimuscarinics and opioid analgesics.
Pregnant women: The safety of Domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated teratogenic effects on the foetus. Lactating mother: Domperidone may precipitate galactorrhoea and improve post-natal lactation. It is secreted in breast milk but on very small quantities, insufficient to be considered harmful.
Domperidone should be used with absolute caution in case of children because there may be an increased risk of extrapyramidal reactions in young children because of an incompletely developed blood brain barrier.
Store in a cool and dry place, protected from light.